journal article·2024-07Open access

Engineering Microorganisms for Cancer Immunotherapy

Dingkang Liu, Lichao Yu, Haibo Rong, Lubin Liu, Jun Yin

Advanced Healthcare Materials· Volume 13· Issue 18

Abstract

Abstract Cancer immunotherapy presents a promising approach to fight against cancer by utilizing the immune system. Recently, engineered microorganisms have emerged as a potential strategy in cancer immunotherapy. These microorganisms, including bacteria and viruses, can be designed and modified using synthetic biology and genetic engineering techniques to target cancer cells and modulate the immune system. This review delves into various microorganism‐based therapies for cancer immunotherapy, encompassing strategies for enhancing efficacy while ensuring safety and ethical considerations. The development of these therapies holds immense potential in offering innovative personalized treatments for cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · Bacteriophages and microbial interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Jiangsu Key Laboratory of Druggability of Biopharmaceuticals State Key Laboratory of Natural Medicines School of Life Science and Technology China Pharmaceutical University No. 639 Longmian Avenue Nanjing 211198 China

Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Nanjing Medical University Affiliated Cancer Hospital Nanjing 210009 China

Department of Obstetrics and Gynecology Women and Children's Hospital of Chongqing Medical University No. 120 Longshan Road Chongqing 401147 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Jiangsu Province · Fundamental Research Funds for the Central Universities

References (100+)

Show source-provided references
1. 10.1126/science.aar406010.1126/science.aar4060 ↗
2. 10.1038/ni.270310.1038/ni.2703 ↗
3. 10.1038/nbt.272510.1038/nbt.2725 ↗
4. 10.1016/j.jconrel.2023.01.04110.1016/j.jconrel.2023.01.041 ↗
5. 10.3390/cancers1302021010.3390/cancers13020210 ↗
6. 10.1038/s41392-021-00506-610.1038/s41392-021-00506-6 ↗
7. 10.1038/nrc367010.1038/nrc3670 ↗
8. 10.1038/s41419-019-1549-610.1038/s41419-019-1549-6 ↗
9. 10.1186/s12943-020-01234-110.1186/s12943-020-01234-1 ↗
10. 10.1093/annonc/mdw21710.1093/annonc/mdw217 ↗
11. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
12. 10.1021/acsnano.3c1078410.1021/acsnano.3c10784 ↗
13. 10.34133/research.005210.34133/research.0052 ↗
14. 10.1002/adma.20230484510.1002/adma.202304845 ↗
15. 10.1126/sciadv.adg327710.1126/sciadv.adg3277 ↗
16. 10.34133/2021/986287610.34133/2021/9862876 ↗
17. 10.1038/nrc293410.1038/nrc2934 ↗
18. Salis H. · 2009 · 194
19. 10.1038/nature2134910.1038/nature21349 ↗
20. 10.1038/nrmicro314010.1038/nrmicro3140 ↗
21. 10.1158/0008-5472.CAN-14-253810.1158/0008-5472.CAN-14-2538 ↗
22. 10.1038/nrm376710.1038/nrm3767 ↗
23. 10.1146/annurev-immunol-051116-05230210.1146/annurev-immunol-051116-052302 ↗
24. 10.1038/nrurol.2014.1510.1038/nrurol.2014.15 ↗
25. 10.1086/52334110.1086/523341 ↗
26. 10.1016/j.biopha.2020.11040910.1016/j.biopha.2020.110409 ↗
27. 10.1007/s10875-012-9708-x10.1007/s10875-012-9708-x ↗
28. 10.1038/ncomms1236510.1038/ncomms12365 ↗
29. 10.1371/journal.pone.014796010.1371/journal.pone.0147960 ↗
30. 10.1158/1078-0432.CCR-11-212110.1158/1078-0432.CCR-11-2121 ↗
31. 10.1126/scitranslmed.aaa351910.1126/scitranslmed.aaa3519 ↗
32. 10.1038/s41467-018-03733-810.1038/s41467-018-03733-8 ↗
33. 10.1016/j.tim.2021.01.00810.1016/j.tim.2021.01.008 ↗
34. 10.1111/cmi.1317510.1111/cmi.13175 ↗
35. 10.3389/fimmu.2021.64231610.3389/fimmu.2021.642316 ↗
36. 10.1111/j.1600-065X.1997.tb01002.x10.1111/j.1600-065X.1997.tb01002.x ↗
37. 10.2119/molmed.2015.0021410.2119/molmed.2015.00214 ↗
38. 10.3390/vaccines603004810.3390/vaccines6030048 ↗
39. 10.1016/j.semcancer.2021.05.01210.1016/j.semcancer.2021.05.012 ↗
40. 10.1016/j.lfs.2020.11829610.1016/j.lfs.2020.118296 ↗
41. 10.1021/acsnano.1c0981810.1021/acsnano.1c09818 ↗
42. 10.1002/advs.20200357210.1002/advs.202003572 ↗
43. 10.1038/s12276-019-0297-010.1038/s12276-019-0297-0 ↗
44. 10.1016/j.addr.2022.11429510.1016/j.addr.2022.114295 ↗
45. 10.1016/j.trecan.2020.11.00410.1016/j.trecan.2020.11.004 ↗
46. 10.1074/jbc.M60561620010.1074/jbc.M605616200 ↗
47. 10.1016/j.micres.2020.12668510.1016/j.micres.2020.126685 ↗
48. 10.1007/s40588-019-00132-510.1007/s40588-019-00132-5 ↗
49. 10.1136/jitc-2022-00583910.1136/jitc-2022-005839 ↗
50. 10.1155/2018/239780810.1155/2018/2397808 ↗
51. 10.3389/fmicb.2021.66948810.3389/fmicb.2021.669488 ↗
52. 10.1186/s13045-020-00922-110.1186/s13045-020-00922-1 ↗
53. 10.1038/s41571-022-00719-w10.1038/s41571-022-00719-w ↗
54. 10.1126/science.282.5392.133210.1126/science.282.5392.1332 ↗
55. 10.1126/science.274.5286.37310.1126/science.274.5286.373 ↗
56. 10.1016/S1535-6108(03)00330-110.1016/S1535-6108(03)00330-1 ↗
57. 10.2217/fmb.12.410.2217/fmb.12.4 ↗
58. 10.1200/JCO.2014.58.337710.1200/JCO.2014.58.3377 ↗
59. 10.2174/156800961766617022212503510.2174/1568009617666170222125035 ↗
60. 10.3109/08830185.2013.82342010.3109/08830185.2013.823420 ↗
61. 10.3390/cancers1205113910.3390/cancers12051139 ↗
62. 10.1038/s41467-019-08599-y10.1038/s41467-019-08599-y ↗
63. 10.3389/fmicb.2021.70729010.3389/fmicb.2021.707290 ↗
64. 10.1158/0008-5472.CAN-19-206210.1158/0008-5472.CAN-19-2062 ↗
65. 10.1146/annurev-virology-092818-01555010.1146/annurev-virology-092818-015550 ↗
66. 10.3390/cancers1102019810.3390/cancers11020198 ↗
67. 10.1056/NEJMoa220202810.1056/NEJMoa2202028 ↗
68. 10.1016/j.intimp.2023.11072210.1016/j.intimp.2023.110722 ↗
69. 10.1038/mt.2010.16110.1038/mt.2010.161 ↗
70. 10.1200/JCO.2022.40.16_suppl.856110.1200/JCO.2022.40.16_suppl.8561 ↗
71. 10.1038/s41417-020-0176-910.1038/s41417-020-0176-9 ↗
72. 10.3390/ijms2212621010.3390/ijms22126210 ↗
73. 10.3390/cells1006154110.3390/cells10061541 ↗
74. 10.1158/1078-0432.CCR-16-290010.1158/1078-0432.CCR-16-2900 ↗
75. 10.1038/s41388-019-0870-y10.1038/s41388-019-0870-y ↗
76. 10.1186/s12943-022-01574-010.1186/s12943-022-01574-0 ↗
77. 10.1038/s41587-019-0404-810.1038/s41587-019-0404-8 ↗
78. 10.3389/fimmu.2019.0099010.3389/fimmu.2019.00990 ↗
79. 10.3390/cancers1306138310.3390/cancers13061383 ↗
80. 10.1186/s40425-018-0495-710.1186/s40425-018-0495-7 ↗
81. 10.1080/21645515.2020.184088710.1080/21645515.2020.1840887 ↗
82. 10.1080/14712598.2019.160066910.1080/14712598.2019.1600669 ↗
83. 10.1038/s41423-020-00613-410.1038/s41423-020-00613-4 ↗
84. Wang X. · J. Biomed. Sci. Res. · 2022 · 4 · 2
85. 10.1016/bs.aivir.2016.07.00110.1016/bs.aivir.2016.07.001 ↗
86. 10.1016/j.omto.2021.05.00710.1016/j.omto.2021.05.007 ↗
87. 10.1016/j.nano.2013.08.00910.1016/j.nano.2013.08.009 ↗
88. 10.1002/smll.20230711110.1002/smll.202307111 ↗
89. 10.2174/187152061866618102914081410.2174/1871520618666181029140814 ↗
90. 10.1016/j.biomaterials.2022.12176310.1016/j.biomaterials.2022.121763 ↗
91. 10.1021/acsnano.1c0872010.1021/acsnano.1c08720 ↗
92. 10.3389/fphar.2021.69905410.3389/fphar.2021.699054 ↗
93. 10.3390/molecules2504084310.3390/molecules25040843 ↗
94. 10.1128/JVI.01537-1010.1128/JVI.01537-10 ↗
95. 10.1038/s41467-022-34791-810.1038/s41467-022-34791-8 ↗
96. 10.3390/v1106056210.3390/v11060562 ↗
97. 10.3390/cancers1302034210.3390/cancers13020342 ↗
98. 10.1089/hum.2020.27110.1089/hum.2020.271 ↗
99. 10.1016/j.tranon.2022.10153010.1016/j.tranon.2022.101530 ↗
100. 10.1080/17474086.2021.197280210.1080/17474086.2021.1972802 ↗